In 2009, AFP-L3 was approved as a cancer biomarker by the FDA (Food and Drug Administration) in the USA [8] and is highly evaluated for HCC-specific biomarkers now [9,10,11,12,13]. The gene discussed is AFP; the disease is hepatocellular carcinoma.